Partnering and financial advisory for the life sciences

We help our clients navigate the turbulent waters of business development,
always with our sights on achieving a successful outcome

About Us

  • Lighthouse BioPartners was founded in the Spring of 2015
  • Located near Research Triangle Park, in Cary, North Carolina
  • We have large and small pharma operational experience and are registered investment bankers
  • Our focus is on business development advisory, including:
    • in-licensing/buyside
    • out-licensing/sellside
    • scientific/partnership collaborations
    • raising capital to advance our clients’ development programs
  • Expertise working with large pharma, specialty pharma, diagnostics/devices and biotech
  • Our clients include companies at all stages of development, from preclinical to commercial stage
  • We work diligently toward a successful transaction, including all aspects of a licensing or financing process:
    • preparation of materials and presentations
    • outreach strategy and execution
    • due diligence
    • transaction execution
Therapeutic Experience:
  • Allergy/Immunology
  • Anti-infectives
  • Cardiovascular
  • CNS/Neurology
  • Dermatology
  • Diabetes/Metabolic
  • Diagnostics/Devices
  • Gastroenterology
  • Gene therapy
  • Hematology
  • Men’s Health
  • Nephrology
  • Oncology/Immuno-therapy
  • Orphan/Rare Diseases
  • Ophthalmology
  • Pediatrics
  • Respiratory
  • Rheumatology
  • Urology
  • Vaccines
  • Women’s Health

Meet Us at These Upcoming Conferences

BIO International

June 5-8, 2023

Boston, MA

Bio-Europe, Fall

November 6-8, 2023

Munich, Germany

Our Team

Steven L. Levine, M.B.A.

Partner

30+ years experience in biopharma including Hybritech, Abbott, J&J and GSK with roles spanning R&D, sales, commercial analysis, marketing, and business development. Advisory work on a number of transactions including M&A, licensing and financing. MBA, University of Michigan. Registered representative with M&A Securities Group, Inc.

David J. Tomasso, M.B.A.

Partner

 30+ years experience in business development, financial evaluation and analysis, sales, marketing and manufacturing. Previous experience with Merck, King, Halozyme, Ratio, and Genprex. MBA from Columbia University. Registered representative with M&A Securities Group, Inc.

Transactions

iX Biopharma

Exclusive license of proprietary sublingual ketamine

November 2021

Click here for press release 

Scioto Biosciences

Series B Investment from Genome & Company

Up to $26.5 Million

August 2020

Click here for press release

Chemical Solutions

Acquired by SGS

May 2019

Click here for press release

Undisclosed

License of rights to pain product

November 2016

XOMA

Divestiture of CMC Biologics Manufacturing Facility to Agenus

November 2015

Undisclosed

License of rights to develop and commercialize pain product

September 2015

 Chamow & Associates

Acquired by Alira Health

December 2020

Click here for press release 

Immedica

Acquired Novartis Ophthalmology Products for Europe

October 2019

Click here for press release

Pulmokine

License of worldwide rights to its inhaled PDGFR inhibitor for PAH and other portfolio programs to Gossamer Bio. 

Up to $303 million + Tiered Royalty

October 2017

PhosImmune

Acquired by Agenus

December 2015

XOMA

Divestiture of Biodefense Program to Nanotherapeutics

November 2015

Contact Us

Steven L. Levine

Phone: (919) 270-7323
Email: [email protected]

David J. Tomasso

Phone: (919) 368-0184
Email: [email protected]

The principals of Lighthouse BioPartners are licensed investment banking agents, offering securities through M&A Securities Group, Inc., an unaffiliated broker-dealer. Member FINRA/SIPC. 4151 N. Mulberry Drive, Suite 252 Kansas City, MO 64116. The testimonials presented here do not guarantee future performance or success.

Copyright © 2023 Lighthouse BioPartners, LLC. All Rights Reserved.